Impact of Immune Status on Secondary Infections in Patients With Acute Respiratory Failure

semi-quantitatively with Herpes simplex (negative / slightly positive / positive and strongly positive) in blood or bronchial lavage

as absolute copy number per milliliter of blood or bronchioalveolar lavage

absolute copy number per milliliter of blood or bronchioalveolar lavage

Absolute number per nanoliter and percentage of lymphocytes

Absolute number per nanoliter and percentage of lymphocytes.

Aabsolute number per nanoliter and percentage of lymphocytes

Absolute number per nanoliter and percentage of lymphocytes

in molecules per cell

Days until the first successful spontaneous breathing trial.

Extracorporeal membrane oxygenation is measured in days

Costs of treatment are measured by costs of particular microbiological diagnostics and therapy.

ITS mortality and hospital mortality are measured.

Routine patient treatment data - score is measured numerically (0 - 24) Routine patient treatment data.

Routine patient treatment data - score is measured numerically (0 - 163)

Classified recording of previous illnesses (e.g. haematological diseases, tumour diseases, chronic heart failure, etc.) from the medical file.

Results of microbiological diagnostics (growth- and molecular-based diagnostics) by specifying the name of the pathogen.

Volumes administered, incl. transfusions and coagulation factors

Recording of ventilation parameters such as airway, ventilation mode and start of ventilation weaning.

Name of catecholamines, inotropes and vasopressors

Number of days with dose of norepinephrine > 0.1 µg/kg/min for more than 30 min or equivalent dose of other catecholamines.

Organ damage measured by routine laboratory

Diagnoses as the cause of ARDS, but also newly acquired diagnoses such as critical illness myopathy / polyneuropathy, renal failure.

Administration of immunosuppressants like corticosteroid, chemotherapy, monoclonal antibodies within the last 3 months.